The next presentations this autumn will be an exciting talk by Kaspar Broch
with title: What can translational research offer clinical studies?
Kaspar Broch leads the Research group for clinical cardiology at Oslo University Hospital, Rikshospitalet. In collaboration with his research group, he has successfully designed, obtained funding for, and conducted several clinical studies.
His main focus has been on proof-of-concept randomised controlled trials.
The results of trials such as the SCHEDULE trial (Andreassen, Am J Transplant 2015) and the HITTS trial (Nytrøen, Circulation 2019) have changed existing practices at Oslo University Hospital, whereas others, such as the EVRICA trial (Broch, PlOS One 2015), the BAR trial (Broch, Heart 2015), and the IronIC trial (Brautaset Englund, J Heart Lung Transplant 2021) have confirmed existing practices.
Yet others, such as the ASSAIL-MI trial (Broch and Anstensrud, Journal of the American College of Cardiology 2021) have opened up exiting prospects for novel treatments.
Publications by Kaspar Broch
